S-52 Skin toxicity from chemo- and targeted therapy M.E. Lacouture1, N.V. Martin1, S. Ortiz1, V. Pacifico2, J. Guitart1, T. Kuzel1, D.P. West1 1Northwestern University, Dermatology, Chicago, United States of America 2University La Sapienza Polo Pontito, Dermatology, Rome, Italy Purpose: Cutaneous toxicity develops in nearly 90% of patients (pts) treated with the multi-targeted kinase inhibitors (MKIs) sorafenib and sunitinib. These debilitating dermatologic toxicities lead to dose reduction and/ or treatment cessation in up to 20% of patients receiving MKIs for advanced renal cell carcinoma, causing identification and management of such events to be of critical importance. We propose to evaluate the frequency, severity, and management of these toxicities related to the use of these drugs, using data obtained from a specialty multidisciplinary dermatology-oncology clinic dedicated to the management of cancer therapy-related side effects, the Skin and Eye Reactions to Inhibitors of EGFR and kinaseS (SERIES) Clinic. Methods: We conducted an evaluation of clinical data from 6 pts with MKI-induced cutaneous toxicities who were managed in the SERIES Clinic. Three pts were treated with sorafenib; 3 with sunitinib. After a baseline visit, the pts were followed up in windows of 2–4, 5–9, and 10– 14 weeks. Clinical presentations, photographs, and histologic specimens were evaluated. Observed MKI-induced toxicities included: seborrheic dermatitis-like rash (SDR); alopecia/hair depigmentation; flushing; splinter hemorrhages; hand/foot skin reactions (HFSR) with hyperkeratotic and tender lesions; nodulocystic lesions. Results: Of the 3 pts treated with sorafenib, all experienced SDR and HFSR, while 1 had nodulocystic lesions, 1 had flushing, and 1 had hair depigmentation. Of the 3 treated with sunitinib, all experienced SDR, while 2 had HFSR, and 1 had hair depigmentation. The HSFR experienced in 5 out of 6 total pts responded to topical urea 40% cream. The SDR experienced in all 6 pts responded to topical pimecrolimus cream. Successful management of these toxicities allowed for continued anticancer therapy as well as an increased quality of life in all 6 pts. Conclusions: Increasing use of MKIs makes it essential to characterize the dermatologic side effect profile. Early identification and treatment of cutaneous toxicities are crucial to alleviate patient discomfort, improve quality of life, and to minimize treatment interruption/cessation. Early and proactive management with topical agents such as calicineurin inhibitors, corticosteroids, and urea may allow for continued lifesaving anticancer therapy. 2007 Meeting Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.